Microbiotica vs Opentrons
Side-by-side comparison of AI visibility scores, market position, and capabilities
Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.
About
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.
Opentrons democratizes lab automation with 10,000+ OT-2 and Flex robotic systems deployed globally; raised $200M+ including $20M Series C in Nov 2025; partnered with BD and HighRes for AI agent-to-agent workflows.
About
Opentrons Labworks is a New York-based life sciences company that designs and manufactures affordable, open-source liquid-handling robots for research laboratories. Founded in 2014, Opentrons'' mission is to democratize biology by making advanced lab automation accessible to life scientists at any institution — from academic labs with limited budgets to leading pharmaceutical companies. Its flagship products, the OT-2 and the newer Opentrons Flex, are programmable robotic platforms that automate repetitive liquid-handling tasks such as PCR setup, nucleic acid extraction, ELISA assays, and next-generation sequencing sample preparation.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.